Search
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalLifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through...
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsTreosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigationalTreosulfan is a prodrug alternative to busulfan for myeloablative conditioning prior to hematopoietic stem cell transplantation. It was approved by the EMA in June 2019 and by the FDA in January 2025 for use in combination with fludarabine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsTezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigationalTezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was ap...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRibociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalRibociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can e...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsCapmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigationalCapmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesNiraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First appr...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InducersErtugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigationalErtugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 20...
Categories: P-glycoprotein substratesPrulifloxacin
go.drugbank.com/drugs/DB11892InvestigationalPrulifloxacin has been investigated for the treatment of Urinary Tract Infection.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsIlaprazole
go.drugbank.com/drugs/DB11964InvestigationalIlaprazole has been investigated in Helicobacter Infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationalNirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. Desmoid tumors are typically characterized by aberrant activation in Notch signaling. Interaction between the n...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates